Dusilová Tereza, Kovář Jan, Laňková Ivana, Thieme Lenka, Hubáčková Monika, Šedivý Petr, Pajuelo Dita, Burian Martin, Dezortová Monika, Miklánková Denisa, Malínská Hana, Svobodová Šťastná Petra, Poledne Rudolf, Hájek Milan, Haluzík Martin
Institute for Clinical and Experimental Medicine, 140 21 Prague, Czech Republic.
Department of Physiology, Faculty of Science, Charles University, 128 44 Prague, Czech Republic.
J Clin Med. 2024 Oct 13;13(20):6100. doi: 10.3390/jcm13206100.
: Metabolic-dysfunction-associated steatotic liver disease (MASLD) represents a major clinical complication of obesity. : In this study, we used magnetic resonance (MR) methods to determine the effect of obesity treatment with semaglutide, a GLP-1 receptor agonist, on the liver fat content and selected metabolic variables. We investigated whether treatment would affect the acute response of liver fat to glucose and fructose administration and whether it would affect the fatty acid profile of VLDL-triglycerides. Sixteen obese non-diabetic men underwent a 16-week dietary intervention and 16-week treatment with subcutaneous semaglutide in a crossover design without a washout period. The order of the interventions was randomized. : After treatment, body weight of the subjects decreased by 5% and liver fat by a third, whereas dietary intervention had no impact on these parameters. The decrease in liver fat with semaglutide did not correlate with changes in body weight and other measures of adiposity and was unrelated to improved insulin sensitivity. : The proportion of palmitic and palmitoleic acids in VLDL-triglycerides decreased after treatment, suggesting that the beneficial effects of semaglutide on liver fat are mediated by the suppression of de novo lipogenesis.
代谢功能障碍相关脂肪性肝病（MASLD）是肥胖的主要临床并发症。在本研究中，我们使用磁共振（MR）方法来确定用胰高血糖素样肽-1（GLP-1）受体激动剂司美格鲁肽治疗肥胖对肝脏脂肪含量和选定代谢变量的影响。我们研究了该治疗是否会影响肝脏脂肪对葡萄糖和果糖给药的急性反应，以及是否会影响极低密度脂蛋白（VLDL）甘油三酯的脂肪酸谱。16名肥胖非糖尿病男性采用交叉设计进行了16周的饮食干预和16周的皮下注射司美格鲁肽治疗，无洗脱期。干预顺序是随机的。治疗后，受试者体重下降了5%，肝脏脂肪减少了三分之一，而饮食干预对这些参数没有影响。司美格鲁肽使肝脏脂肪减少与体重变化和其他肥胖指标无关，且与胰岛素敏感性改善无关。治疗后，VLDL甘油三酯中棕榈酸和棕榈油酸的比例降低，这表明司美格鲁肽对肝脏脂肪的有益作用是通过抑制从头脂肪生成来介导的。
